but they help show that Takeda Pharmaceutical Co. Is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, TAK feels like a great value stock at the ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug reduced blood procedures among patients with a rare type of cancer in a ...

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals ... around 115 million people in the US, and standard therapy is eradication with a combination ...

The S&P 500 has sunk to the start of 2025. But most Wall Street strategists argue there's likely still more upside for stocks to end the year. Chinese technology giant Baidu released two new ...

--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE ... as an add-on to standard of care treatment. The study met its primary endpoint and all ...